Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

Switching from oral to topical dutasteride can cause shedding due to changes in DHT levels, and it's recommended to overlap both treatments to minimize this effect. Topical dutasteride may cause scalp irritation, and the user is considering dutasteride mesotherapy as an alternative.

The user has been using finasteride for 15 months, minoxidil for 4.5 months, and estrogen monotherapy for 4.5 months. Their current regimen includes finasteride, minoxidil, alfatradiol, and estradiol gel.

The conversation discusses hair loss treatments, specifically using dutasteride (0.5mg daily) with no side effects reported after two months. It also mentions the health benefits of one meal per day and the low incidence of side effects.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Topical dutasteride with microneedling is effective for androgenetic alopecia, improving hair thickness and density. Further research is needed to confirm long-term efficacy.

A user who has been using Pyrilutamide for 19 days, experiencing some hair thickening in the right temple and crown area but also having ball ache after microneedling; other users offer advice, caution and skepticism as to whether results can be seen in such a short time.

Dutasteride mesotherapy is discussed as a potential treatment for hair loss, with some users suggesting it offers a slight boost when combined with oral minoxidil, though it's costly. Concerns about side effects and systemic absorption are noted, with alternatives like topical dutasteride and microneedling suggested for home use.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The user is starting dutasteride mesotherapy and seeks information on checking serum DHT levels in Germany. They previously tried finasteride but experienced unpleasant side effects.

Mesotherapy Dutasteride is considered highly effective for reducing scalp DHT and potentially reversing hair loss. However, one user reported systemic side effects and no improvement in hair loss.

The user experienced significant hair growth using 0.5 mg Dutasteride and 5 mg oral Minoxidil over 10 weeks, with initial shedding but no side effects. The treatment was surprisingly affordable at $7 for a 3-month supply.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

A user reported using a topical hair loss treatment containing Minoxidil, Dutasteride, and other ingredients, noting a significant drop in DHT levels and a smaller decrease in testosterone after three months. They also mentioned microneedling, feeling fine with unchanged or increased libido, and taking Cialis as a preventative measure for performance issues.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

A 21-year-old male is using a topical treatment for hair loss, including Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and Hydrocortisone, along with derma rolling. He reports no side effects from the treatment and seeks feedback on its effectiveness for hair regrowth.

A 25-year-old uses oral minoxidil, dutasteride, and a shampoo with minoxidil and ketoconazole for hair loss, experiencing progress and increased body hair. Users discuss the effectiveness of these treatments, with some suggesting that dutasteride is primarily responsible for hair thickening.

Dutasteride mesotherapy may stabilize hair loss and improve hair without significantly affecting serum DHT levels, but it can still have systemic effects. Users discuss using topical and oral dutasteride, with some experiencing side effects and considering hair transplants.

The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.

The conversation is about purchasing dutasteride solution for mesotherapy, with a suggestion to make it using dutasteride capsules and oils. A user shared a link to a potential supplier and mentioned using dutasteride with microneedling.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.

The user had been using Minoxidil and Dutasteride with micro-needling but experienced hair loss after switching Minoxidil brands. Their doctor prescribed oral Minoxidil and Tretinoin, but the pharmacist suggested isotretinoin might be a more cost-effective alternative.